1. Pink Sheet
  2. >>Vaccines

After ACIP Gambit, Pfizer, GSK Take RSV Vaccines To US FDA Adcomm

 
• By Sarah Karlin-Smith and Bridget Silverman

The Vaccines and Related Biological Products Advisory Committee is scheduled to consider the RSV vaccine candidates on 28 February and 1 March.

RSV virus
ACIP members preferred a higher age floor for the RSV vaccines in older adults. • Source: Shutterstock

Pfizer Inc. and GSK plc’s respiratory syncytial virus (RSV) vaccines for older adults appear headed for easy US Food and Drug Administration approval, but their use in younger seniors – those 60 to 64 – may be limited by the Centers for Disease Control and Prevention following the most recent Advisory Committee on Immunization Practices on the products.

FDA’s Vaccines and Related Biological Products Advisory Committee will take separate safety and efficacy votes 28 February on Pfizer’s Abrysvo...

More from Vaccines

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 
• By Eliza Slawther

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.

US FDA’s June Approval Forecast: Infection Prevention, Cancer And HAE

 
• By Bridget Silverman

Upcoming FDA user fee goal dates include novel products from a busy lung cancer pipeline, a single-dose passive immunization against RSV for infants, what could be the first oral HAE acute treatment, and a first-in-class HAE preventive antibody.

Pink Sheet Podcast: US FDA’s Private Pharma CEO Tour, HHS Changes COVID-19 Vaccine Advice

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.

US FDA Meeting Drought Ends … With A Vengeance

 
• By Michael McCaughan

The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.

More from Pink Sheet